{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:58:09Z","timestamp":1763017089562,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1317,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA31946"],"award-info":[{"award-number":["CA31946"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.bbmt.2011.01.016","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T04:17:05Z","timestamp":1296793025000},"page":"1395-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901"],"prefix":"10.1016","volume":"17","author":[{"given":"Thomas","family":"Shea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Isola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Anne","family":"Baxter-Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouros","family":"Owzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Linker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.01.016_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib2","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib4","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib5","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib6","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.535.535","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib10","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"I-Tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.01.016_bib12","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib13","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2599.2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group after a follow up of 58 months","volume":"112","author":"Buske","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib15","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib17","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.01.016_bib18","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib19","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib22","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib23","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib25","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.772.772","volume":"112","author":"Hiddemann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib27","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib28","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib29","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Verdonck","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/annonc\/mdn044","article-title":"Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma","volume":"19","author":"Arcaini","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib31","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2007.14.4204","article-title":"Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey","volume":"26","author":"Tarella","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib32","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7041","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"26","author":"Laport","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.01.016_bib35","article-title":"Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma results in an improved progression free survival when compared to autologous stem cell transplantation. An analysis from the Lymphoma Working Party of the EBMT","volume":"112","author":"Robinson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib36","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after non-myeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib39","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.486.486","article-title":"Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients with advanced indolent NHL and CLL: CALGB 109901","volume":"110","author":"Shea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib41","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.01.016_bib42","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib43","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V85.7.1954.bloodjournal8571954","article-title":"Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers","volume":"85","author":"Sharf","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib44","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: A survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.01.016_bib46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2009.07905.x","article-title":"Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"147","author":"Avivi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.01.016_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.01.016_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.50.50","article-title":"Tandem autologous-allogeneic nonmyeloablative sibling transplant in relapsed follicular lymphoma leads to impressive progression free survival with minimal toxicity","volume":"114","author":"Cohen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.01.016_bib50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.01.016_bib51","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:40:12Z","timestamp":1761057612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1083879111000784"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.01.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}